Marksans Pharma Ltd.

₹325.6

3.3 (1%)

MARKSANS Share Price

Pharmaceuticals & Biotechnology

As on October 1, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 14,736.9 Cr

P/E Ratio35.31

Dividend Yield0.28 %

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	331.83	Bearish
10-DMA	333.53	Bearish
20-DMA	330.21	Bearish
50-DMA	309.4	Bullish
100-DMA	278.73	Bullish
200-DMA	227.94	Bullish

Historical Performance

1 Year

95.4%

3 Years

195.9%

5 Years

372.6%

10 Years

519%

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Net Sales	29,509	26,228	21,774	18,521	14,908
Total Expenditure	23,502	20,902	17,188	15,128	12,320
Other Income	825	663	504	593	419
Operating Profit	6,833	5,990	5,090	3,986	3,007
Interest	241	117	112	91	84
Depreciation	986	834	743	519	448
Profit Before Tax	5,606	5,040	4,235	3,377	2,475
Consolidated Net Profit	4,179	3,806	3,137	2,663	1,846
Adjusted EPS	9	8	7	6	5

Compounded Sales Growth

10 Years:27

5 Years:16.5

3 Years:9.8

TTM:2.4

Compounded Profit Growth

10 Years:39.7

5 Years:12.1

3 Years:9.4

TTM:1.9

Stock Price CAGR

10 Years:19.2

5 Years:36.4

3 Years:43.8

TTM:95.6

Return on Equity

10 Years:0.2

5 Years:4.5

3 Years:6.9

last year:9.2

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Share Capital	453	453	453	453	409
Total Reserves	29,745	24,216	20,197	16,998	10,682
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	2,682	2,729	2,052	843	571
Other Current Liabilities	1,187	1,172	706	422	968
Short Term Borrowings	296	231	291	416	413
Total Liabilities	38,479	32,396	26,810	21,904	16,601
Capital Work in Progress	148	90	54	72	7
Long Term Loans & Advances	225	263	329	189	42
Currents Investments	---	7	270	5	4
Short Term Loans and Advances	760	812	598	355	318
Total Current Assets	27,227	22,041	18,625	16,753	12,251
Total Assets	38,479	32,396	26,810	21,904	16,601
Adjusted Book Value	67	54	46	39	27

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a high PE of 35.31, indicating expensive valuation or elevated growth expectations.
Over the last three years, the stock delivered a strong 3-year price CAGR of 43.8%, indicating sustained price appreciation.
The stock carries a beta of 1.0, indicating volatility broadly in line with the market.
In the last financial year, the company reported an EBITDA of ₹6833 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹29509 million, indicating a large and established business.

Investment Calculator

Investment Amount:₹

Investment Amount: ₹ 1000000

Current Value: ₹ 1955203.3

No. of Shares: 6005 (Approx)

Performance:95.5%

955203.3

NIFTY Performance: -9.9%

1 day Top Gainers